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OVA-specific CD8+T cells do not express
granzyme B during anterior chamber
associated immune deviation
Abstract Purpose: To examine an-
tigen (Ag)-specific CTL response
during anterior chamber associated
immune deviation (ACAID).
Methods: OVA or OVA257-264
peptide was injected into the anterior
chamber (AC) of C57BL/6 mice.
There were 16 mice in each ACAID
group induced with OVA or OVA257-
264 peptide. The mice were primed
by SC injection with OVA or OVA
257-264 peptide in complete Freund’s
adjuvant (CFA) on day 7. Ag-specific
CD8+T cells in spleens were ana-
lyzed on day 14 using Pentamer
H-2Kb-SIINFEKL(OVA257-264
peptide). IFN-γ ELISPOT and intra-
cellular granzyme B staining were
used to characterize the CTL re-
sponse. Twelve mice in each group
immunized with OVA or OVA257-
264 peptide in CFA served as posi-
tive controls. Twelve normal mice
served as negative controls and 12
receiving injection of CFA as CFA
controls for studying the influence of
CFA on the Ag-specific CTL re-
sponse. Result: The results showed
that anterior chamber inoculation of
OVA or OVA257-264 peptide could
induce ACAID as evidenced by an
impaired DTH response. The fre-
quency of Ag-specific CD8+T cells in
ACAID mice was not different
from that in mice challenged with
Ags in CFA only (positive controls).
IFN-γ production by these cells in
ACAID mice was not different
compared to positive controls. How-
ever, Ag-specific CD8+T cells in
ACAID mice failed to secrete gran-
zyme B. Mice challenged only with
OVA peptide and CFA also showed a
granzyme B negative CD8+T cell
response. Ag-specific CTL response
induced by CFA alone was similar
with the negative control.
Conclusion: These results show that
the frequency of Ag-specific CD8+T
cells is not altered during ACAID.
The Ag-specific CTL response during
ACAID is characterized by the ab-
sence of granzyme B expression.
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Introduction
It is well known that CD8+T lymphocytes are important to
the adaptive immune response against viruses, the rejection
of allogeneic grafts, etc. [1, 4, 7, 27, 35, 36]. Their role in
ACAID, a deviant immune response elicited by intracam-
eral injection of antigen, has however not been well
addressed. ACAID is characterized by a deficiency in
delayed-type hypersensitivity (DTH) responses and de-
creased expression of IgG isotypes [24, 28]. Furthermore,
allogeneic tumor cells injected into the AC grow progres-
sively, whereas these cells do not expand when injected
elsewhere in the body [26]. This progressive growing of
tumor cells in the AC has been attributed to ACAID. As
CD8+Tcells are actively involved in the inhibition of tumor
cells, a number of studies have been performed to
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investigate their role in ACAID. It has been found that CTL
activity is impaired in ACAID [13, 15, 34], thereby resulting
in the progressive growth of tumor cells in the AC. Further
studies have shown that a CTL response is present in the
spleen during ACAID [16], but is not active within the eye.
Most studies addressing the CTL response during
ACAID were performed with the conventional technique,
i.e. the 51Chromium (51Cr) release assay. However, this
assay has been shown to have a number of disadvantages,
such as high spontaneous release, inefficient labeling of
target cells, a low sensitivity, and health risks associated
with gamma irradiation [5, 12, 17, 20, 21, 33]. Novel
techniques to quantitatively and qualitatively assay Ag-
specific CD8+T cells, for instance Tetramer and cytokine
ELISPOTassays, have been developed during recent years.
More recently, Pentamer, a more sensitive technique with
the same principle as Tetramer, has been used for the study
of Ag-specific CD8+T cells. Commercially available
SIINFEKL(OVA257-264 peptide) Pentamer contains 5
fluorescent MHC-peptide complexes facing in the same
planar orientation, which allows higher avidity and an
increase in fluorescent signal. The application of the
Pentamer may provide a new insight into the role of Ag-
specific CD8+T cells during ACAID and was therefore the
subject of the study described here. In this study, the
Pentamer was used to enumerate CD8+T cells, an IFN-γ
ELISPOTassay and intracellular granzyme B staining were
used to functionally evaluate the Ag-specific CD8+T cells.
Our results show that the expansion of Ag-specific CD8+T
cells expressing IFN-γ is not affected in ACAID, but these
cells have lost their capacity to express granzyme B. This
may explain the generally observed phenomenon that the
CTL response is impaired during ACAID.
Materials and methods
Experimental animals
Specific pathogen-free female C57BL/6 (B6; H-2b) mice,
6–8 weeks of age, were purchased from the animal facility
at the Sun Yat-sen University, China. All mice were treated
according to the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research.
Antigens and adjuvant
OVA (grade VI) was purchased from Sigma-Aldrich
(Steinheim, Germany) and dissolved in phosphate-buffered
saline (PBS) at a concentration of 20 mg/ml. OVA257-264
peptide (Purity>95%) (Anaspec, Inc., San Jose, Calif.,
USA) was dissolved in sterile distilled H2O at three differ-
ent concentrations (20 mg/ml, 30 mg/ml and 40 mg/ml).
CFA containing heat-killed Mycobacterium tuberculosis
strain H37Ra was purchased from Sigma-Aldrich.
Induction of ACAID
ACAID was induced as described previously using
microinjection of antigen into AC of the eye [25]. Briefly,
mice were anesthetized and 5 μl antigens were injected into
the AC on day 0 by a glass micropipette with a sterile infant
feeding tube mounted onto a 0.1 ml Hamilton (Hamilton,
Reno, Nev., USA) syringe. OVA or OVA257-264 peptide
(250 μg) emulsified 1:1 in CFA were used for SC
immunization on day 7. Normal B6 mice served as
negative controls, and those receiving an SC immunization
as positive controls. Four mice were used in each group and
experiments were repeated at least 3 times.
DTH assay
To determine the DTH response, mice receiving an SC
immunization on day 7. On day 14, the mice were
challenged with 400 μg OVA or peptide into the left ear
pinnae to evoke a DTH response. The right ear pinnae
received 20 μl sterile PBS alone and served as a control.
The ear thickness was measured using a Mitutoyo microm-
eter (MTI Corp., Paramus, N.J., USA). The DTH response
was determined by the following formula: specific ear
swelling= [(24-h-0-h) measurement for the experimental
ear−(24-h-0-h) measurement for the negative control ear]
μm.
MHC Pentamer reagent, staining
and flow cytometry analysis
The mice were killed on day 14. The spleens were removed
and dispersed into a single-cell suspension. Erythrocytes
were lysed by Tris-NH4Cl (0.83% in 0.01 M Tris-HCl).
The PE-labeled Pentamer (Proimmune, Oxford, UK) was
used to assay the OVA-specific CD8+T cells. Fc receptors
were blocked with anti-mouse CD16/CD32 Fc-RIIIyII
(clone 93; eBioscience, San Diego, Calif., USA) and then
stained with Pentamer for 40 min at 4°C. After washing,
the cells were costained with anti-CD8a-FITC (Proim-
mune) and anti-CD3-PEcy5 (eBioscience). Then the
samples were resuspended and analyzed by FACScan
(Becton Dickinson Immunocytometry Systems, San Jose,
Calif., USA) using CELLQUEST software. From a live
lymphocyte gate, CD8+T cell gate was drawn and
enumerated at least 100,000 CD8+T cells for analysis.
IFN-γ ELISPOT assays and image analysis
IFN-γ-producing CD8+T cells in the spleens were
enumerated using mouse IFN-γ-specific ELISPOT assays.
The ELISPOT assay was performed according to the
manufacture’s instruction. Briefly, 96-well PVDF plates
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(BD Biosciences Pharmingen, San Jose, Calif., USA) were
coated overnight at 4°C with 0.5 μg/well of purified anti-
IFN-γ. The plates were then washed once blocked for 2 h
with complete RPMI. CD8+T cells (2×105) purified by
MiniMACS device (Miltenyi Biotec, Bergisch Gladbach,
Germany) and APCs (3×105) from the syngeneic mice in
each well were stimulated with OVA or OVA257-264
peptide (70 μg/ml at final concentration) for 24 h at 37°C in
5% CO2. The cells were removed by two washes with
sterile distilled H2O and three additional washes with
PBS/0.05% Tween20 (PBST). Biotinylated anti-IFN-γ
antibody (0.2 μg) was added to each well and incubated
at room temperature for 2 h. Horseradish peroxidase-
conjugated streptavidin was added and the spots were
visualized with the Final Substrate Solution. The spots
were automatically analyzed by the SeriesIImmunoSpot
Analyzer (Cellular Technology Ltd, Cleveland, Ohio,
USA) specifically designed for the ELISPOT assay as
described previously [8].
Intracellular granzyme B staining
After preparation of single-cell suspensions and lysis of
erythrocytes in these suspensions, the cells were resus-
pended in complete RPMI 1640 at a density of 2×106 cells
per ml. For intracellular cytokine staining of granzyme B,
the cells (4×106) were stimulated with OVA or OVA257-
264 peptide (100 μg/ml) and IL-2 (100 IU/ml) at 37°C for
5 h in the presence of Brefeldin A (10 ng/ml) (BioLegend,
San Jose, Calif., USA) in the last 4 h before staining. After
incubation, the cells were fixed and permeabilized. The
cells were then costained with anti-CD3-FITC
(eBioscience), anti-CD8-PEcy5 (eBioscience) and anti-
granzyme B-PE (eBioscience). The samples were subse-
quently analyzed on FACScan and CD8+Tcells were gated.
Matched isotypes served as control.
Statistical analysis
Data were subjected to analysis by ANOVA using SPSS
11.0. A value of P<0.05 was considered significantly
different.
Results
Induction of ACAID by OVA
and OVA257-264 peptide
To investigate the frequency of Ag-specific CD8+T cells in
the spleen during ACAID, both OVA and OVA257-264
peptide were used for the induction of ACAID. The DTH
response was evaluated. As this peptide had not been used
previously for the induction of ACAID, we tested the effect
of three different dosages (100 μg, 150 μg and 200 μg).
The DTH responses presented in Fig. 1 show that ACAID
could be successfully induced following intracameral
injection of either OVA or peptide. All OVA peptide
dosages tested effectively induced ACAID as shown by the
inhibited DTH response.
Frequency of Ag-specific CD8+T cells in the spleens
of mice with ACAID
To address the CTL response in ACAID, we first examined
the frequency of splenic Ag-specific CD8+T cells using
Pentamer H-2Kb-SIINFEKL staining. Ag-specific CD8+T
cells were observed, respectively, in 0.10% and 0.11% of
the total CD8+T cell population in the spleens of ACAID
mice induced by OVA or peptide. Ag-specific CD8+T cells
were noted in 0.12% and 0.13%, respectively, of the
CD8+T cells in positive controls immunized by OVA or
peptide (Fig. 2a). There was no significant difference
between the ACAID groups and the positive controls as
regards the frequency of these cells. The frequency of Ag-
specific CD8+Tcells was significantly increased in both the
ACAID groups and positive controls as compared to those
in the negative controls (Fig. 2b).
Secretion of IFN-γ by Ag-specific CD8+T cells
in ACAID
As IFN-γproduction may represent, to a great extent, the
effector response of Ag-specific CD8+T cells [3, 19, 22],
we studied these cells in the spleens of positive controls
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Fig. 1 DTH measurement after the injection of antigens into the
AC. Mice received an injection of native OVA (100 μg) or OVA
257–264 peptide (100 μg or 150 μg or 200 μg) into the anterior
chamber (AC) on day 0. On day 7, mice were primed with either
OVA or OVA 257–264 peptide in CFA. Ears of mice were
challenged, on day 14, with either OVA or its peptide. DTH was
expressed as ear swelling (in micrometers) 24 h after ear challenge.
Naive mice were used as negative controls, and mice that received
an SC immunization but not an AC injection served as positive
controls. Bars represent the mean±SEM (n=12) of ear measure-
ments. * Indicates mean values significantly decreased as compared
to the positive controls, P<0.001
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immunized by OVA and peptide and found that the average
numbers of spots were 167 and 162 per 2×105 CD8+Tcells,
respectively. In the spleens of ACAID mice induced with
OVA or peptide, the average numbers were 158 and 160,
respectively. There was no significant difference between
ACAID groups and the positive controls concerning the
number of IFN-γspots (Fig. 3).
Secretion of granzyme B by Ag-specific CD8+T cells
in ACAID
As granzyme B is an important index of the lytic function
of effector CD8+T cells [10, 11], this enzyme was assayed
by intracellular staining to functionally evaluate the Ag-
specific CD8+T cells. The results, as displayed in Fig. 4,
showed that there was no detectable granzyme B produced
by Ag-specific CD8+T cells in the spleens of ACAID mice.
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Fig. 2 Flow cytometry analysis of Ag-specific CD8+T cells per
100,000 CD8+T cells in the spleens of different groups. Negative:
normal B6 mice. ACAID (OVA/Pep): mice received an AC injection
of either OVA or OVA257-264 peptide. Seven days later mice were
immunized with OVA or its peptide in CFA. Positive (OVA/Pep):
mice received an SC. injection of OVA/OVA257-264 peptide in
CFA. CFA was subcutaneously injected and used to examine the
influence of adjuvant on the frequency of Ag-specific CD8+T cells.
We gated on CD8+T cells and enumerated 100,000 CD8+T cells.
FITC-labeled anti-CD8 is shown on the horizontal axis, and PE-
labeled Pentamer is shown on the vertical axis. Stained cells in the
upper right quadrangle represent antigen specific CD8+T cells. Each
analysis was performed at least 3 times to verify the results. Results
represent the mean values from 3 separate experiments (4 mice/
group). *P<0.001 compared with negative control
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A similar result was also found in the mice receiving SC
immunization with peptide in CFA. In the spleens of mice
challenged with OVA in CFA, 0.52% of Ag-specific
CD8+T cells were found to produce granzyme B. There
was a significant difference when comparing the produc-
tion of granzyme B by Ag-specific CD8+T cells between
the ACAID groups and the positive control receiving OVA
immunization.
Discussion
In this study, we show that the CTL response, mediated by
Ag-specific CD8+T cells in ACAID induced by OVA or
OVA257-264 peptide, is characterized by the absence of
granzyme B. Granzyme B is released by cytotoxic T cells
and leads to apoptosis in target cells through cleavage of
caspase-3. Using the Pentamer H2-Kb-SIINFEKL tech-
nique, we found that the frequency of splenic Ag-specific
CD8+T cells could be induced by an SC challenge with
antigen in CFA, but that a previous intracameral antigen
injection did not alter this frequency. Similar results were
obtained using either OVA or its peptide. The capacity to
express IFN-γ by splenic Ag-specific CD8+T cells was
also not altered in ACAID mice. These findings suggest
that the expansion of Ag-specific CD8+T cells is not
influenced by the intracameral injection of antigens and
that the previously presumed clonal deletion, i.e. absence
or decreased frequency of Ag-specific CD8+T cells, may
not be the reason for the impaired CTL response in
ACAID. Our findings support earlier studies by the group
of Kapp [14], who followed antigen specific CD8+T cells
during ACAID and showed that this population of cells
expanded in vivo but lost their cytotoxic function. As the
production of granzyme B generally represents the killing
function of CD8+T cells, it is important to co-stain
granzyme B and Pentamer for FACS analysis. However,
we did not do this experiment due to the very limited cell
numbers of Ag-specific CD8+T cells identified with
Pentamer was not sufficient for this analysis. Intracellular
staining for granzyme B was, therefore, only performed to
compare its production in ACAID mice and positive
controls. Our study failed to demonstrate the production
of granzyme B in ACAID mice. These data suggest that
the absence of granzyme B production may be responsible
for the impairment of the killing function of Ag-specific
CD8+T cells during ACAID. It is interesting to note that
the frequency of granzyme B+CD8+T cells identified by
FACS analysis was much higher than that of Ag-specific
CD8+T cells measured by Pentamer. The explanation
could be that in vitro measurement of the frequency of
granzyme B+CD8+T cells is performed after exposure of
CD8+T cells to OVA257-264 peptide and IL-2, which
could result in extra expansion of effector CD8+T cells
secreting granzyme B. Further studies are needed to
correlate the absence of granzyme B and cytotoxic activity
of CD8+T cells during ACAID. As granulysin [23],
perforin [23] and Fas-FasL pathway [30] are also involved
in the mechanisms by which CD8+T cells kill the target
cells, a further point of interest would be to address their
roles in the CTLs in mice undergoing ACAID.
Loss of granzyme B staining in CD8+T cells was also
observed in our experimental group challenged SC. with
OVA peptide in the presence of CFA (Fig. 4). Peptide
immunization did result in the generation of antigen
specific CD8+T cells and the expression of IFN-γ. An
interesting result has been reported by Porgador et al [18] in
which a weak CTL response in the spleen was observed
after immunization with OVA257-264 peptide emulsified
in IFA. The reason for the difference in the CTL response
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Fig. 4 Frequency of CD8+T cells producing granzyme B in the
spleens of the different groups of mice as identified by flow
cytometry analysis. Only the positive controls receiving OVA in
CFA showed a detectable granzyme B response. The results are
representative for three independent experiments. * P<0.001
compared with negative control
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Fig. 3 Frequency of IFN-γ-producing Ag-specific CD8+T cells in
the spleens of different groups using ELISPOT assay. There were
2×105 CD8+T cells per well and the cells were stimulated by 70
μg/ml OVA or OVA257-264 peptide for 24 h. As shown in this
representative graph, ACAID (OVA/OVA257-264 peptide) and
positive controls (OVA/OVA257-264 peptide) mice exhibited
significantly higher frequencies of IFN-γ-producing Ag-specific
CD8+ T cells than the negative controls. The results are representa-
tive for three separate experiments. * P<0.001 compared with
negative control
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between the IFA group in the study of Porgador et al [18]
and CFA groups in our study is not known. A previous
study has suggested that microenviroments induced by
different adjuvants might be responsible for this difference
in CTL response [10]. Further studies are needed to
investigate whether similar mechanisms are involved in the
impaired granzyme B expression seen in ACAID and that
following SC peptide immunization.
Effector CD8+T cells are normally defined by their
capability of producing high amounts of IFN-γ and lysing
virus-infected cells [11]. It has been established that CD8+T
cells lyse target cells by utilizing perforin and granzyme B.
Both proteins are constitutively expressed within the
preformed granules of effector CD8+T cells [2, 6, 13, 29,
32]. Evidence has emerged that granzyme B may exert
cytolytic activity in the absence of the perforin channel and
can even penetrate the cells to activate the apoptotic
cascade [18].
In this study, we found that the Ag-specific CD8+T cells
secreted large amount of IFN-γ almost equal to that
produced in the positive controls. Therefore, these Ag-
specific CD8+T cells seem not to be the regulatory cells
characterized as little IFN-γ production [9]. It is not clear
yet which mechanisms are involved in the process whereby
these Ag-specific CD8+T cells lose their cytotoxic capacity
or their ability to express granzyme B.
In summary, our study showed, at a single cell level, that
the expansion of Ag-specific CD8+T cells is not influenced
during ACAID, but that the ability to express granzyme B
is impaired. The deficiency in granzyme B production by
these Ag-specific CD8+T cells may be one of reasons for
the impaired killing function generally observed in animals
undergoing ACAID. This study may open an avenue for
the further investigation of mechanisms involved in
ACAID and perhaps the manipulation of intraocular
tumors.
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